PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
1183629452	rs3219151	PMID:24061200	GABRA6	Allele C is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele T.	no	= 0.587	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184746653	rs2844665	PMCID:PMC3173287		Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	yes	= 2.69E-7	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
1184988832	HLA-B*56:02	PMID:23025739	HLA-B	HLA-B *56:02 is associated with drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	not stated		3		Oceanian	Toxicity	false	Case report. A 32-year old man, 33-year-old man and 43-year-old woman, all Indigenous Australian, presented with drug-induced hypersensitivity syndrome (DIHS; also known as drug reaction with eosinophilia and systemic symptoms (DRESS)) after receiving phenytoin. Genotyping revealed that all three patients carried the HLA-B*56:02 allele, with one patient being homozygous for the allele.	phenytoin
982047886	CYP2C19*2	PMID:23551241	CYP2C19	CYP2C19 *2 is not associated with increased risk of severe cutaneous adverse drug reactions when treated with phenytoin in children as compared to CYP2C19 *1.	no	= 0.52	40	40	East Asian	Toxicity	true		phenytoin
1450969200	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMCID:PMC6989102	CYP2C9	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.	yes	< 0.01	796		Multiple groups, White, non-Hispanic; Asian; Black; White, Hispanic	Metabolism/PK	false	Compared to CYP2C9 extensive metabolizers, low-intermediate/poor metabolizers had a 21.3-pg/mL increase (95% CI: 13.6–29.0pg/mL; P<0.01)	phenytoin
1183629441	rs2279020	PMID:24061200	GABRA1	Allele A is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	no	= 0.8361	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1449566312	HLA-DRB1*15:02:01	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.30	13	40	East Asian	Toxicity	true		phenytoin
1451120240	rs1801133	PMCID:PMC6689870	MTHFR	Genotype AA is associated with increased risk of Psychotic Disorders due to phenobarbital and phenytoin in men with Epilepsy.	no		1		Unknown	Toxicity	false	Case report of a patient who developed psychotic symptoms following initiation of treatment with phenytoin and phenobarbital. Patient was found to have the AA genotype and had several vitamin deficiencies. Psychotic symptoms improved with vitamin supplementation and switching phenytoin and phenobarbital treatment to lamotrigine, although the patient still experienced monthly seizures. Please note that alleles have been complemented to the positive strand.	phenobarbital; phenytoin
1184989363	CYP2C9*1; CYP2C9*3	PMID:25096692	CYP2C9	CYP2C9 *3 is associated with increased concentrations of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1.	yes	= 0.022	40		East Asian	Metabolism/PK	false	In individuals who experienced severe cutaneous adverse reactions (SCARs) when taking phenytoin, those who carried the CYP2C9*3 allele had significantly higher levels of plasma phenytoin, as compared to those who did not carry the *3 allele.	phenytoin
1450376288	CYP2C9*3	PMCID:PMC5798660	CYP2C9	CYP2C9 *3 is not associated with risk of Maculopapular Exanthema due to phenytoin.	no	= 0.08	52	472	European	Toxicity	false		phenytoin
1445400112	rs2032582	PMID:26122019	ABCB1	Allele A is not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to allele C.	no	= 0.54	64		Latino	Metabolism/PK	false	or T. No significant difference in dose-corrected phenytoin concentrations was seen between the CC, AC + CT or AA + AT + TT genotypes. Univariate analysis. Please note that alleles have been complemented to the plus chromosomal strand.	phenytoin
1449566321	HLA-DRB1*16:02:01	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *16:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.77	13	40	East Asian	Toxicity	true		phenytoin
1183629461	rs211037	PMID:24061200	GABRG2	Allele C is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele T.	no	= 0.718	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184988858	HLA-B*15:02:01	PMID:22429379	HLA-B	HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.	not stated		2		East Asian	Toxicity	false	Case report with two female Han Chinese patients. The first patient developed maculopapular rash after receiving carbamazepine and then again after receiving oxcarbazepine. No rash occurred after treatment with levetiracetam. The second patient developed Stevens-Johnson Syndrome after receiving phenytoin, then developed a maculopapular eruption after receiving phenobarbital and then again after receiving carbamazepine. No reaction occurred after treatment with topiramate. The authors state that this study reports cross-reactivity to these anti-epileptics.	carbamazepine; oxcarbazepine; phenobarbital; phenytoin
1183629456	rs2229944	PMID:24061200	GABRB2	Allele G is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele A.	no	= 0.1233	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1448612933	CYP2C19*1; CYP2C19*2	PMCID:PMC5377478	CYP2C19	CYP2C19 *1/*2 is not associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C19 *1/*1.	no	= 0.33	351		Central/South Asian	Toxicity	false	Concentrations were assessed in relation to toxic concentrations of phenytoin compared to *1/*1.	phenytoin
1449565307	CYP2C9*3	PMID:25597548	CYP2C9	CYP2C9 *3 is associated with increased concentrations of phenytoin.	no		3		European	Dosage,Metabolism/PK	false	Series of three case reports of patients with elevated phenytoin concentrations and designated as poor or very poor metabolizers of phenytoin following genetic testing. Two cases also presented with possible symptoms of phenytoin toxicity. Case 1 was heterozygous for CYP2C9*3 and CYP2C19*2, Case 2 was homozygous for CYP2C9*3 and Case 3 was heterozygous for CYP2C9*3.	phenytoin
981858971	CYP2C9*1	PMCID:PMC2014334	CYP2C9	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*2.	yes	= 0.009	101		Near Eastern	Metabolism/PK	false		phenytoin
827922299	HLA-A*03:01:01:01	PMCID:PMC3428903	HLA-A	HLA-A *03:01:01:01 is not associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	no	= 0.746	44	1296	European	Toxicity	false	Risk of increased risk of cutaneous adverse reactions. Allele was reported as  HLA-A*3101.	phenytoin
1449566276	HLA-DRB1*12:01:01	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *12:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.43	13	40	East Asian	Toxicity	true		phenytoin
1183701162	HLA-B*51:01:01	PMID:24236482	HLA-B	HLA-B *51:01:01 is not associated with Stevens-Johnson Syndrome when treated with phenytoin.	no	= 0.1037	9	2878	East Asian	Toxicity	false	Phenotype:  Steven-Johnson Syndrome/ Toxic epidermal necrolysis. The association was not statistically significant after Bonferroni correction. The allele used here represents *51:01.	phenytoin
1449566285	HLA-DRB1*12:02:01	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *12:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
1449566294	HLA-DRB1*14:54	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *14:54 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
1447948922	HLA-B*56:02	PMID:26928377	HLA-B	HLA-B *56:02 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.	yes	=  0.0274	39	92	East Asian	Toxicity	false	Association is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).	phenytoin
1449566303	HLA-DRB1*15:01:01:01	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *15:01:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
981859014	CYP2C9*1	PMCID:PMC2014334	CYP2C9	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *2/*2.	yes	= 0.02	101		Near Eastern	Metabolism/PK	false		phenytoin
1449565733	CYP2C9*1; CYP2C9*54	PMID:27163851	CYP2C9	CYP2C9 *54 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *54 had a relative clearance of 388.3% compared to *1.	phenytoin
827921693	rs28399504	PMID:22641027	CYP2C19	Genotype AG is associated with Drug Toxicity when treated with diazepam and phenytoin in children with Epilepsy.	no		1		Unknown	Metabolism/PK,Toxicity	true	in a single case. Plasma phenytoin levels were higher than expected (69 mgL(-1); normal range: 10-20 mgL(-1))	diazepam; phenytoin
1449566240	HLA-DRB1*08:02:01	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *08:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
981859021	CYP2C9*1	PMCID:PMC2014334	CYP2C9	CYP2C9 *1/*1 is associated with decreased plasma concentration when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*3.	yes	= 0.001	101		Near Eastern	Metabolism/PK	false		phenytoin
1449565742	CYP2C9*1; CYP2C9*55	PMID:27163851	CYP2C9	CYP2C9 *55 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *55 had a relative clearance of 32.0% compared to *1.	phenytoin
1450969140	CYP2C9*1; CYP2C9*2	PMCID:PMC6989102	CYP2C9	CYP2C9 *1/*2 is associated with increased concentrations of phenytoin as compared to CYP2C9 *1/*1.	yes	< 0.01	876		Multiple groups, White, non-Hispanic; Asian; BlackWhite, Hispanic	Metabolism/PK	false	Compared to CYP2C9 extensive metabolizers (*1/*1 by the absence of *2 or *3), high-intermediate metabolizers (*1/*2) had an 8.6 pg/mL increase in mean dose-ad- justed phenytoin blood concentrations [95% confidence interval (CI): 2.3–14.8pg/mL; P<0.01]	phenytoin
827921686	CYP2C9*1; CYP2C9*2	PMID:22641027	CYP2C9	CYP2C9 *2/*2 is associated with Drug Toxicity when treated with diazepam and phenytoin in children with Epilepsy.	no		1		Unknown	Metabolism/PK,Toxicity	true	in a single case. Plasma phenytoin levels were higher than expected (69 mgL(-1); normal range: 10-20 mgL(-1))	diazepam; phenytoin
1449566249	HLA-DRB1*08:03:02	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *08:03:02 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.10	13	40	East Asian	Toxicity	true		phenytoin
1449565751	CYP2C9*1; CYP2C9*56	PMID:27163851	CYP2C9	CYP2C9 *56 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *56 had a relative clearance of 643.2% compared to *1.	phenytoin
1184755407	HLA-B*15:02:01	PMID:19018717	HLA-B	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	not stated	= 1.0E-4	18		East Asian	Toxicity	false	This allele was not observed in any of the patients.	carbamazepine; phenobarbital; phenytoin; zonisamide
1449566258	HLA-DRB1*09:01:02	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *09:01:02 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.40	13	40	East Asian	Toxicity	true		phenytoin
981859027	CYP2C9*3	PMID:11673755	CYP2C9	CYP2C9 *3/*3 is associated with increased toxicity when treated with phenytoin.	no					Toxicity	false	"IMPORTANT NOTE: This is a case report, including one patient only. Patient has genotype of CYP2C9 *3/*3. The elimination half-life in the patient was 5 times longer than the mean value generally quoted (103 hours vs. 22 hours).
The patient manifested neurologic signs compatible with phenytoin intoxication."	phenytoin
769249152	rs2229107	PMID:16220110	ABCB1	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype TT.	yes	= 0.015	109		Sub-Saharan African	Metabolism/PK,Other	false	[stat_test: Jonckheere-Terpstra test]	phenytoin
1450376232	rs78239784	PMCID:PMC5798660	CFHR4	Allele G is associated with increased risk of Maculopapular Exanthema due to phenytoin as compared to allele T.	yes	= 4.5E-11	65	560	European	Toxicity	false	rs78239784 is an intronic SNP in complete LD with the missense variant rs35274867. rs35274867 was filtered out of analysis during quality control, so was not itself analyzed.	phenytoin
1449566267	HLA-DRB1*11:01:01	PMCID:PMC5467955	HLA-DRB1	HLA-DRB1 *11:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
1446902370	HLA-B*15:02:01	PMID:25647819	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	yes	= 0.047	15	74	East Asian	Toxicity	false	However, p<0.001 was considered statistically significant after adjusting for multiple comparisons using Bonferroni correction. Using this criteria, this association is no longer significant. Controls were patients tolerant to phenytoin after taking it for at least 3 months without developing a skin rash.	phenytoin
1184989377	CYP2C9*1; CYP2C9*3	PMID:25096692	CYP2C9	CYP2C9 *3 is not associated with dose of phenytoin in people with severe cutaneous adverse reactions as compared to CYP2C9 *1/*1.	no	> 0.05	40		East Asian	Dosage	false	In individuals who experienced severe cutaneous adverse reactions (SCARs) when taking phenytoin, the average daily dose of phenytoin was not significantly different between those who carried the CYP2C9*3 allele and those who did not.	phenytoin
981859044	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:21338443	CYP2C9	CYP2C9 *1/*2 + *1/*3 is associated with increased adverse drug reactions when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	yes	= 0.008	182		European	Toxicity	false	IMPORTANT NOTE: The final analysis included 91 SNPs and two CNVs from from 17 candidate genes. For each gene, p values were corrected for the number of polymorphisms tested. Of 182 patients treated with PHT, 49 reported ADRs and 91 reported no ADRs. In the remaining patients, insufficient clinical data were available.	phenytoin
1448612922	CYP2C9*1; CYP2C9*3	PMCID:PMC5377478	CYP2C9	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	yes	= 0.002	351		Central/South Asian	Toxicity	false	Concentrations in *1/*3 were 3x more likely to have toxic concentrations of phenytoin compared to *1/*1.	phenytoin
1449566213	HLA-C*08:01	PMCID:PMC5467955	HLA-C	HLA-C *08:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.36	13	40	East Asian	Toxicity	true		phenytoin
981859041	CYP2C9*1; CYP2C9*3	PMID:12707459	CYP2C9	CYP2C9 *1/*3 is associated with increased toxicity when exposed to phenytoin.	no					Toxicity	false	IMPORTANT NOTE: This is a case report (41 yrs old woman). Patient has genotype of CYP2C9 *1/*3. She has elevated plasma phenytoin levels. The patient manifested neurologic signs compatible with phenytoin intoxication.	phenytoin
1184746741	rs3130931	PMCID:PMC3173287	POU5F1	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	yes	= 7.78E-7	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
981954797	rs1128503	PMID:18812236	ABCB1	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
981349397	HLA-B*15:02:01	PMID:18637831	HLA-B	HLA-B *15:02:01 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine or phenytoin in people with Epilepsy.	no		21	50	East Asian	Toxicity	false		carbamazepine; phenytoin
981859049	CYP2C9*1; CYP2C9*3	PMID:15385837	CYP2C9	CYP2C9 *1/*3 is associated with increased steady state concentration per dosage when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	yes	< 0.05	169		East Asian	Metabolism/PK	false	Steady-State Concentrations (CSS)/dose was  2.7 ± 1.1 for *1/*1 and 4.3 ± 1.8 for *1/*3.	phenytoin
1449565706	CYP2C9*1; CYP2C9*51	PMID:27163851	CYP2C9	CYP2C9 *51 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *51 had a relative clearance of 479.0% compared to *1.	phenytoin
981859061	CYP2C9*1; CYP2C9*3	PMID:10774639	CYP2C9	CYP2C9 *1/*3 is associated with increased toxicity when treated with phenytoin.	no					Toxicity	false	IMPORTANT NOTE: This is a case report (Japanese male). Patient has genotype of CYP2C9 *1/*3 and CYP2C19 *1/*3. He has elevated plasma phenytoin levels. The patient manifested neurologic signs compatible with phenytoin intoxication.	phenytoin
981349390	HLA-B*15:02:01	PMID:18637831	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	yes	= 0.005	10	50	East Asian	Toxicity	false		phenytoin
1449566231	HLA-C*15:05:01	PMCID:PMC5467955	HLA-C	HLA-C *15:05:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.43	13	40	East Asian	Toxicity	true		phenytoin
981954805	rs2032582	PMID:18812236	ABCB1	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1449565715	CYP2C9*1; CYP2C9*52	PMID:27163851	CYP2C9	CYP2C9 *52 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *52 had a relative clearance of 0.2% compared to *1.	phenytoin
981859058	CYP2C9*1; CYP2C9*3	PMID:19030785	CYP2C9	CYP2C9 *1/*3 is associated with increased toxicity when exposed to phenytoin.	no					Toxicity	false	IMPORTANT NOTE: This is a case report (53 yrs old asian woman). Patient has genotype of CYP2C9 *1/*3. She has elevated plasma phenytoin levels. The patient manifested neurologic signs compatible with phenytoin intoxication.	phenytoin
769250209	rs1045642	PMID:17529887	ABCB1	Allele G is associated with increased likelihood of drug resistance when treated with phenytoin in people with Epilepsy as compared to allele A.	yes	< 0.001	63	50	Near Eastern	Efficacy	false		phenytoin
981859069	HLA-B*15:02:01	PMID:20235791	HLA-B	HLA-B *15:02:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	yes	= 0.0041	26	113	East Asian	Toxicity	false		phenytoin
1184755431	HLA-B*07:02:01	PMID:19018717	HLA-B	HLA-B *07:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	not stated	= 1.0E-4	18		East Asian	Toxicity	false	This allele was not observed in any of the patients.	carbamazepine; phenobarbital; phenytoin; zonisamide
1449565724	CYP2C9*1; CYP2C9*53	PMID:27163851	CYP2C9	CYP2C9 *53 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *53 had a relative clearance of 448.0% compared to *1.	phenytoin
1184746726	rs3815087	PMCID:PMC3173287	PSORS1C1	Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele G.	yes	= 2.89E-27	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
981859064	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMID:11434505	CYP2C9	CYP2C9 *1/*2 + *1/*3 are associated with decreased dose when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	yes	< 0.01	60		European	Metabolism/PK	false		phenytoin
1451117820	CYP2C9*1; CYP2C9*3	PMID:31646624	CYP2C9	CYP2C9 *3 is associated with increased risk of Exanthema when treated with phenytoin as compared to CYP2C9 *1/*1.	yes	= 0.0017	33	723	East Asian	Toxicity	false	CYP2C9*3 carrier status was significantly associated with phenytoin-induced eruption in the Japanese Population.	phenytoin
1447949001	HLA-B*51:01:01	PMID:26928377	HLA-B	HLA-B *51:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	yes	= 0.0381	21	92	East Asian	Toxicity	false	Association for HLA-B*51:01 is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).	phenytoin
1449565410	rs1029359343	PMID:26658169	CYP2C9	Genotype AG is associated with increased risk of Drug Toxicity due to phenytoin in children.	no		1		Unknown	Toxicity	true	Case study of a pediatric patient with phenytoin toxicity who was found to be a compound heterozygote at rs544027339 and rs1029359343 in CYP2C9.	phenytoin
1184989223	HLA-B*15:02:01	PMID:25096692	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	yes	= 0.025	48	130	East Asian	Toxicity	false	The HLA-B*15:02 allele was more frequent in patients who developed phenytoin-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to phenytoin-tolerant controls. However, no significant results were seen when considering drug reactions with eosinophilia and systemic symptoms (DRESS) or severe cutaneous adverse reactions (SCARs - both SJS/TEN and DRESS). Note that p-values were corrected using Bonferroni's correction.	phenytoin
1447948993	HLA-B*15:02:01	PMID:26928377	HLA-B	HLA-B *15:02:01 is not associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	no	> 0.05	21	92	East Asian	Toxicity	false	Association is not significant using Fisher’s exact test comparing the positive alleles of SCARs patients with the tolerant controls or Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).	phenytoin
1449565930	rs3758581	PMCID:PMC5820983	CYP2C19	Allele G is associated with increased risk of drug reaction with eosinophilia and systemic symptoms due to phenytoin in children as compared to allele A.	no		1		Unknown	Toxicity	true	Case study of a pediatric patient who developed DRESS shortly after beginning phenytoin treatment. Subsequent genetic analysis revealed that the patient carried the G allele at rs3758581, but the paper does not state whether the patient had one or two copies of the allele. Please note that the paper also refers to this SNP as being present in CYP2C9 rather than in CYP2C19.	phenytoin
1184521237	G6PD deficiency	PMCID:PMC1689719	G6PD	G6PD deficiency is not associated with Hemolysis when treated with phenytoin.	not stated		2		East Asian	Toxicity	false	Red blood cells from G6PD deficient patients were labelled with 51-Cr and cross-transfused into G6PD-normal male recipients. The half-life of these labelled red blood cells was determined before and after drug treatment- drug treatment was not associated with decreased half life.  *Note: genotyping to determine underlying G6PD deficient variant was not carried out*.	phenytoin
655387520	rs1051740	PMID:19952982	EPHX1	Allele T is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele C.	yes	= 0.02	157		Multiple groups	Toxicity	false	(maternal genotype effects outcome in child)	phenytoin
1449565430	CYP2C9*1; CYP2C9*2	PMID:27163851	CYP2C9	CYP2C9 *2 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *2 had a relative clearance of 94.8% compared to *1.	phenytoin
1448613065	rs2740574	PMID:28343093	CYP3A4	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
655387523	rs2234922	PMID:19952982	EPHX1	Allele G is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele A.	yes	= 0.03	157		Multiple groups	Toxicity	false	(maternal genotype effects outcome in child)	phenytoin
1448613071	rs2687116	PMID:28343093	CYP3A4	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele A.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1449565937	HLA-A*02:01	PMCID:PMC5467955	HLA-A	HLA-A *02:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	yes	= 0.042	13	40	East Asian	Toxicity	true	Note that this allele was seen in high linkage disequilibrium with HLA-A*24:02.	phenytoin
1449565950	HLA-A*24:02:01:01	PMCID:PMC5467955	HLA-A	HLA-A *24:02:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	yes	= 0.027	13	40	East Asian	Toxicity	true	Note that this allele was seen in high linkage disequilibrium with HLA-A*02:01.	phenytoin
1448613059	rs3892097	PMID:28343093	CYP2D6	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1184988734	HLA-B*15:02:01	PMID:24897291	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	yes	= 0.0002			East Asian	Toxicity	false	Meta-analysis with four studies. Cases were compared against drug-tolerant controls.	phenytoin
769250168	rs12782374	PMCID:PMC2812115	CYP2C9	Genotypes AA + AG are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GG.	yes	= 0.017	173		European	Dosage,Metabolism/PK	false	Statistics given for haplotype *1B measured by rs71486745delTG and rs12782374G>A.	phenytoin
769250171	rs71486745	PMCID:PMC2812115	CYP2C9	Genotypes GT/del + del/del are associated with decreased dose of phenytoin in people with Epilepsy as compared to genotype GTGT.	yes	= 0.017	173		European	Dosage,Metabolism/PK	false	Statistics given for haplotype *1B measured by rs71486745delTG and rs12782374G>A.	phenytoin
1449565892	CYP2C9*1; CYP2C9*2	PMCID:PMC4868001	CYP2C9	CYP2C9 *1/*2 is not associated with likelihood of adverse events due to phenytoin in children with Epilepsy as compared to CYP2C9 *1/*1.	no	= 0.597	89		Central/South Asian	Toxicity	true	Frequency of gum hypertrophy, ataxia and hirsutism side effects was not associated with the presence of the CYP2C9*2 allele.	phenytoin
769250160	rs71486745	PMCID:PMC2812115	CYP2C9	Allele del is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells.	yes						false	when co-transfected with CAR (NR1I3), suggesting this variant disrupts the CAR binding site in the CYP2C9 promoter.	phenytoin
1450806480	CYP2C9*1; CYP2C9*3	PMID:30270535	CYP2C9	CYP2C9 *3 is associated with increased risk of Maculopapular Exanthema and severe cutaneous adverse reactions when treated with phenytoin as compared to CYP2C9 *1/*1.	yes	= 4.66e-14	172	376	East Asian	Toxicity	false	CYP2C9*3 was strongly associated with phenytoin hypersensitivity in  Asians  (P = 4.66 × 10-14,  OR  =  10.74  for  Taiwan).	phenytoin
1184989197	HLA-B*13:01:01	PMID:25096692	HLA-B	HLA-B *13:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin.	no	> 0.05	48	130	East Asian	Toxicity	false	No significant difference in the frequency of the HLA-B*13:01 allele was seen between phenytoin-tolerant controls and patients with severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reactions with eosinophilia and systemic symptoms (DRESS). Additionally, no significant results were seen when considering SJS/TEN or DRESS individually. Note that p-values were corrected using Bonferroni's correction.	phenytoin
769250164	rs12782374	PMCID:PMC2812115	CYP2C9	Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells.	yes						false	when co-transfected with CAR (NR1I3) or PXR (NR1I2), suggesting this variant disrupts a binding site responsive to CAR and PXR in the CYP2C9 promoter.	phenytoin
769250167	rs12782374	PMCID:PMC2812115	CYP2C9	Genotype AG is associated with increased metabolism of phenytoin as compared to genotype GG.	not stated					Metabolism/PK,Other	false	in human liver samples from individuals who did not have CYP2C9*2(rs1799853 T) or *3 (rs1057910 C). Measured by ratio of formation of (S)- and (R)-p-HPPH in vitro.	phenytoin
1449565399	rs544027339	PMID:26658169	CYP2C9	Genotype GT is associated with increased risk of Drug Toxicity due to phenytoin in children.	no		1		Unknown	Toxicity	true	Case study of a pediatric patient with phenytoin toxicity who was found to be a compound heterozygote at rs544027339 and rs1029359343 in CYP2C9.	phenytoin
1450806472	HLA-B*51:01:01	PMID:30270535	HLA-B	HLA-B *51:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	yes	= 3.45e-3	128	376	East Asian	Toxicity	false	"""HLA-B*51:01  exhibited  marginal  effects  on  the  risk  for  phenytoin-related SJS/TEN, DRESS, and MPE, as a significant association was only observed in total phenytoin hypersensitivity reactions likely due to an issue related to the sample size."""	phenytoin
1450969293	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMCID:PMC6989102	CYP2C9	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with decreased dose of phenytoin as compared to CYP2C9 *1/*1.	yes	= 0.02	382		Multiple groups	Dosage	false	Low-intermediate/poor CYP2C9 genotype was associated with greater odds of having a lower dose by the end of the first year of treatment in the full cohort (OR 1.11; 95% CI: 1.02–1.22; P=0.02).	phenytoin
1450806464	HLA-B*15:02:01	PMID:30270535	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	yes	= 5.09e-6	128	376	East Asian	Toxicity	false	HLA-B*15:02 was significantly associated with phenytoin-SCAR. Of note,  the genetic association of HLA-B*15:02 with phenytoin-SCAR seems to be largely attributed to Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), rather than drug reaction with eosinophilia and systemic symptoms (DRESS).	phenytoin
1184989213	HLA-B*51:01:01	PMID:25096692	HLA-B	HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin.	no	= 0.072	90	130	East Asian	Toxicity	false	No significant difference in the frequency of the HLA-B*51:01 allele was seen between phenytoin-tolerant controls and patients with severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reactions with eosinophilia and systemic symptoms (DRESS). Additionally, no significant results were seen when considering SJS/TEN or DRESS individually. Note that p-values were corrected using Bonferroni's correction.	phenytoin
1450969282	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMCID:PMC6989102	CYP2C9	CYP2C9 *1/*3 + *2/*2 + *2/*3 + *3/*3 are associated with increased risk of Drug Toxicity when treated with phenytoin as compared to CYP2C9 *1/*1.	yes	< 0.01	382		Multiple groups	Toxicity	false	Low-intermediate/ poor metabolizers had a significantly increased risk of a neurological side effect in the full cohort (HR 2.40; 95% CI: 1.24–4.64; P < 0.01) and increased risk, although not significantly, in the seizure subset (HR 2.09; 95% CI: 0.95–4.60; P=0.07).	phenytoin
981858886	CYP2C9*1; CYP2C9*3	PMID:15024534	CYP2C9	CYP2C9 *1/*3 is associated with increased likelihood of diphenylhydantoin-induced skin rash when exposed to phenytoin in neurological patients as compared to CYP2C9 *1/*1.	yes	= 0.007	10	39	Unknown	Toxicity	false		phenytoin
981858881	CYP2C9*1; CYP2C9*3	PMID:20390258	CYP2C9	CYP2C9 *1/*3 is associated with increased risk of phenytoin toxicity when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	yes	= 1.0E-4	58	234	East Asian	Toxicity	false		phenytoin
1445388514	CYP2C9*1; CYP2C9*2	PMID:26122019	CYP2C9	CYP2C9 *1/*1 + *1/*2 are not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy.	no	> 0.05	64		Latino	Metabolism/PK	false	No significant difference in dose-corrected phenytoin concentrations was seen between the *1/*1 and *1/*2 genotypes (p=0.90). Univariate analysis.	phenytoin
1447948937	HLA-C*14:02:01	PMID:26928377	HLA-C	HLA-C *14:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	yes	= 0.0077	39	92	East Asian	Toxicity	false	Association with HLA-C*14:02 is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).	phenytoin
769249041	rs9332131	PMID:16220110	CYP2C9	Allele del is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA.	yes	= 0.001	109		Sub-Saharan African	Metabolism/PK,Other	false	as measured by urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Statistics given for trend with various PM allele vs *1*1. [stat_test: ANOVA]	phenytoin
769249040	rs28371685	PMID:16220110	CYP2C9	Allele T is associated with increased metabolism of phenytoin in people with no disease as compared to genotype CC.	yes	= 0.001	109		Sub-Saharan African	Metabolism/PK,Other	false	as measured by urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Statistics given for trend with various PM allele vs *1*1. [stat_test: ANOVA]	phenytoin
1449565868	CYP2C9*1; CYP2C9*2	PMCID:PMC4868001	CYP2C9	CYP2C9 *1/*2 is not associated with dose of phenytoin in children with as compared to CYP2C9 *1/*1.	no	= 0.89	89		Central/South Asian	Metabolism/PK	true		phenytoin
1450969260	CYP2C9*1; CYP2C9*2	PMCID:PMC6989102	CYP2C9	CYP2C9 *1/*2 is not associated with increased risk of Drug Toxicity when treated with phenytoin as compared to CYP2C9 *1/*1.	no	= 0.46	232		Multiple groups	Toxicity	false	Compared to extensive metabolizers, high-intermediate metabo- lizers did not have increased risk of neurological side effects in the full cohort [hazard ratio (HR) 1.06; 95% CI: 0.53–2.11; P=086], or in the seizure subset (HR 1.31; 95% CI: 0.65–2.65; P=0.46).	phenytoin
1449565877	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMCID:PMC4868001	CYP2C9	CYP2C9 *1/*3 + *2/*3 is not associated with likelihood of adverse events due to phenytoin in children with Epilepsy as compared to CYP2C9 *1/*1 + *1/*2.	no	= 0.597	89		Central/South Asian	Toxicity	true	Frequency of gum hypertrophy, ataxia and hirsutism side effects was not associated with the presence of the CYP2C9*3 allele.	phenytoin
769249039	rs7900194	PMID:16220110	CYP2C9	Allele A is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype GG.	yes	= 0.001	109		Sub-Saharan African	Metabolism/PK,Other	false	as measured by urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Statistics given for trend with various PM allele vs *1*1. [stat_test: ANOVA]	phenytoin
1447948955	HLA-B*38:02:01	PMID:26928377	HLA-B	HLA-B *38:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	yes	= 0.0281	39	92	East Asian	Toxicity	false	Association for *38:02 is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).	phenytoin
769250049	rs1057910	PMCID:PMC4339275	CYP2C9	Genotype AC is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to genotype AA.	not stated		14	290	European	Toxicity	false	Only one heterozygote (AC = *1*3) observed and no homozygotes amongst cases.	phenytoin
1445396733	rs1128503	PMID:26122019	ABCB1	Genotype AG is not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA.	no	= 0.13	64		Latino	Metabolism/PK	false	No significant difference in dose-corrected phenytoin concentrations was seen between the AA and AG genotypes. Univariate analysis. Please note that alleles have been complemented to the plus chromosomal strand.	phenytoin
1447948946	HLA-B*51:01:01	PMID:26928377	HLA-B	HLA-B *51:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	yes	= 0.0163	39	92	East Asian	Toxicity	false	Association for HLA-B*51:01 is not significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).	phenytoin
1449565369	CYP2C9*1; CYP2C9*3	PMID:25998968	CYP2C9	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in children.	no		1		East Asian	Dosage,Metabolism/PK	true	Case report of an infant patient with phenytoin toxicity as a result of elevated phenytoin levels. Genetic testing found that the patient had the CYP2C9 *1/*3 diplotype.	phenytoin
1450806425	HLA-B*13:01:01	PMID:30270535	HLA-B	HLA-B *13:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	yes	= 1.9e-4	128	376	East Asian	Toxicity	false	HLA-B*13:01 was significantly associated with phenytoin-SCAR. Of note,  the genetic association of HLA-B*13:01 with phenytoin-SCAR seems to be largely attributed to drug reaction with eosinophilia and systemic symptoms (DRESS), rather than Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN).	phenytoin
1449565316	CYP2C19*2	PMID:25597548	CYP2C19	CYP2C19 *2 is associated with increased concentrations of phenytoin.	no		1		European	Dosage,Metabolism/PK	false	Case report of a patient with elevated phenytoin concentrations and was found to be heterozygous for CYP2C9*3 and CYP2C19*2 following genetic testing. They were designated as a poor metabolizer of phenytoin.	phenytoin
1447948974	CYP2C9*1; CYP2C9*3	PMID:26928377	CYP2C9	CYP2C9 *3 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin as compared to CYP2C9 *1.	yes	= 0.0266	39	92	East Asian	Toxicity	false	Association is significant using Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9). *2 was genotyped but no carriers in either cases or controls identified.	phenytoin
1448613053	rs9332120	PMID:28343093	CYP2C9	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1447948964	HLA-B*15:02:01	PMID:26928377	HLA-B	HLA-B *15:02:01 is not associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	no	> 0.05	39	92	East Asian	Toxicity	false	Association is not significant using Fisher’s exact test comparing the positive alleles of SCARs patients with the tolerant controls or Bonferroni’s correction for multiple comparison (18 for HLA-A, 26 for HLA-B, 15 for HLA-C, 2 for CYP2C9).	phenytoin
1448613046	rs1065852	PMID:28343093	CYP2D6	Allele A is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele G.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1449565832	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMCID:PMC4868001	CYP2C9	CYP2C9 *1/*3 + *2/*3 are associated with increased concentrations of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2.	yes	= 0.009	89		Central/South Asian	Metabolism/PK	true	Patients who were heterozygous for the CYP2C9*3 allele had significantly higher levels of phenytoin than patients who did not carry the *3 allele. No patients with the *3/*3 diplotype were identified.	phenytoin
1449565846	CYP2C9*1; CYP2C9*2	PMCID:PMC4868001	CYP2C9	CYP2C9 *1/*2 is not associated with concentrations of phenytoin in children with as compared to CYP2C9 *1/*1.	no	= 0.74	89		Central/South Asian	Metabolism/PK	true		phenytoin
1449565855	CYP2C9*1; CYP2C9*2; CYP2C9*3	PMCID:PMC4868001	CYP2C9	CYP2C9 *1/*3 + *2/*3 are not associated with dose of phenytoin in children with as compared to CYP2C9 *1/*1 + *1/*2.	no	= 0.12	89		Central/South Asian	Metabolism/PK	true		phenytoin
769250083	rs1057910	PMID:10901705	CYP2C9	Allele C is associated with decreased metabolism of phenytoin.	no					Metabolism/PK,Other	false	in vitro.	phenytoin
769250082	rs1799853	PMID:10901705	CYP2C9	Allele T is not associated with decreased metabolism of phenytoin.	no					Metabolism/PK,Other	false	in vitro.	phenytoin
1449565339	CYP2C9*3	PMID:25994870	CYP2C9	CYP2C9 *3 is associated with increased risk of severe cutaneous adverse reactions due to phenytoin in children with Epilepsy.	yes	= 0.016	17	326	East Asian	Toxicity	true		phenytoin
981859205	rs2298771	PMCID:PMC3125053	SCN1A	Allele C is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	no	= 0.91	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1447949133	HLA-B*15:02:01	PMID:26927288	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	yes	= 3.6E-4	13	300	East Asian	Toxicity	false	The HLA-B*15:02 allele was significantly more frequent in patients with phenytoin-induced Stevens-Johnson Syndrome (SJS) or toxic epidermal necrolysis (TEN) (SJS/TEN; 61.5%), as compared to phenytoin-tolerant controls (21.9%).	phenytoin
1449565540	CYP2C9*1; CYP2C9*31	PMID:27163851	CYP2C9	CYP2C9 *31 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *31 had a relative clearance of 51.4% compared to *1.	phenytoin
1451151740	rs1045642	PMCID:PMC7221122	ABCB1	Allele G is not associated with resistance to phenytoin in people with Epilepsy as compared to allele A.	no	= 0.34	67		Unknown	Efficacy	false	No significant association between the variant and the number of patients with drug-resistant epilepsy. Please note that alleles have been complemented to the positive strand.	phenytoin
982046605	CYP2C9*1; CYP2C9*3	PMID:9860067	CYP2C9	CYP2C9 *1/*3 is associated with decreased the mean maximal elimination rate (Vmax) when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*1.	not stated		134		East Asian	Metabolism/PK	false		phenytoin
1448994136	CYP2C9*1; CYP2C9*3	PMID:14659971	CYP2C9	CYP2C9 *3 is not associated with increased severity of Gingival Overgrowth when treated with phenytoin in people with Epilepsy as compared to CYP2C9 *1.	no		28		East Asian	Toxicity	false	even though CYP2C9*3 was associated with higher serum phenytoin concentration to drug dose ratio, and higher serum phenytoin was associated with gingival overgrowth however sample size was small (only three *1/*3 and no *3/*3).	phenytoin
1449566048	HLA-B*15:02:01	PMCID:PMC5467955	HLA-B	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.20	13	40	East Asian	Toxicity	true	"for phenytoin alone. Authors state ""we cannot exclude the possibility that HLA-B*15:02 is a risk allele for PTH- or LTG-induced SJS/TEN. Logistic regression analysis revealed an excess risk from the interaction between HLA-A*24:02 and HLA-B*15:02, suggesting that HLA-A*24:02 functions together with HLA-B*15:02 to contribute to aromatic AED–induced SJS/TEN. """	phenytoin
769250001	rs1128503	PMID:16220110	ABCB1	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.	yes	= 0.015	109		Sub-Saharan African	Metabolism/PK,Other	false	as part of a haplotype of four SNPs: IVS6+139C>T, IVS9-44A>G, 1236C>T (rs1128503) and 3435C>T (rs1045642) [stat_test: Jonckheere-Terpstra test].	phenytoin
982046592	CYP2C9*1	PMID:21532277	CYP2C9	CYP2C9 *1/*1 is associated with increased the mean maximal elimination rates (V(max)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3.	yes	< 0.005	20		East Asian	Metabolism/PK	true	"Note: These genotypes are combination of CYP2C9 and CYP2C19.
CYP2C9 *1/*1 + CYP2C19 *1/*1 is associated with increased the mean maximal elimination rates (V(max)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3 and CYP2C19*1/*2 or *1/*3"	phenytoin
1449565549	CYP2C9*1; CYP2C9*33	PMID:27163851	CYP2C9	CYP2C9 *33 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *33 had a relative clearance of 0.4% compared to *1.	phenytoin
1185003437	HLA-B*15:02:01	PMID:25305458	HLA-B	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	not stated	= 0.035	8	13	Central/South Asian	Toxicity	false	The HLA-B*15:02 allele was not observed in those with phenytoin-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) or phenytoin-tolerant controls.	phenytoin
1451151730	rs1057910	PMCID:PMC7221122	CYP2C9	Allele C is associated with increased risk of Ataxia, Diplopia, Dizziness or Dysarthria due to phenytoin in people with Epilepsy as compared to allele A.	yes	= 0.001	67		Unknown	Efficacy	false	The C allele is also referred to in the paper as the CYP2C9*3 allele. Patients carrying the CYP2C9*2 or *3 alleles were significantly more likely to experience vestibular-cerebellar adverse drug reactions.	phenytoin
769250004	rs1045642	PMID:16220110	ABCB1	Allele A is associated with increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG.	yes	= 0.015	109		Sub-Saharan African	Metabolism/PK,Other	false	as part of a haplotype of four SNPs: IVS6+139C>T, IVS9-44A>G, 1236C>T (rs1128503) and 3435C>T (rs1045642) [stat_test: Jonckheere-Terpstra test].	phenytoin
982046599	CYP2C9*1	PMID:21532277	CYP2C9	CYP2C9 *1/*1 is associated with increased the intrinsic metabolic activity (V(max)/K(m)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3.	yes	< 0.005	20		East Asian	Metabolism/PK	true	"Note: These genotypes are combination of CYP2C9 and CYP2C19.
CYP2C9 *1/*1 + CYP2C19 *1/*1 is associated with increased the mean maximal elimination rates (V(max)) when exposed to phenytoin in children Epilepsy as compared to CYP2C9 *1/*3 and CYP2C19*1/*2 or *1/*3"	phenytoin
1449566057	HLA-B*35:01:01:01	PMCID:PMC5467955	HLA-B	HLA-B *35:01:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.25	13	40	East Asian	Toxicity	true		phenytoin
1450823542	HLA-B*56:02	PMCID:PMC6710506	HLA-B	HLA-B *56:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	not stated		1		Oceanian	Toxicity	false	This is a case report of phenytoin DRESS (RegiSCAR DRESS score 7) in an Aboriginal Australian that was associated with HLA-B*56:02 and with CYP2C9*1/*3 genotype.	phenytoin
1449565558	CYP2C9*1; CYP2C9*34	PMID:27163851	CYP2C9	CYP2C9 *34 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *34 had a relative clearance of 72.7% compared to *1.	phenytoin
1451151724	rs3812718	PMCID:PMC7221122	SCN1A	Allele T is not associated with resistance to phenytoin in people with Epilepsy as compared to allele C.	no	= 0.34	67		Unknown	Efficacy	false	No significant association between the variant and the number of patients with drug-resistant epilepsy. Please note that alleles have been complemented to the positive strand.	phenytoin
1184746894	rs9469003	PMCID:PMC3173287	CYCSP5	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	yes	= 1.60E-9	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
1448525637	HLA-C*15:02:01	PMID:27888155	HLA-C	HLA-C *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	yes	< 0.001	9	253	European	Toxicity	false	"The frequency of the COMBINATION of HLA-A*02:01/HLA-C*15:02 was significantly higher in cases of phenytoin-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to a group of patients tolerant to phenytoin, lamotrigine OR carbamazepine (""antiepileptic tolerant controls""). However, when the frequency was compared against patients who were phenytoin-tolerant only, a non-significant result was found. Significant results were also seen when comparing against a general population group."	phenytoin
769146060	rs2606345	PMID:21121773	CYP1A1	Allele A is associated with increased risk of Seizures when treated with carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele C.	yes	= 0.00297	101		Central/South Asian	Efficacy,Metabolism/PK	false	This association was found in women but not in men.  The authors postulate that this is modulated through metabolism of estradiol.	carbamazepine; phenobarbital; phenytoin; valproic acid
981859218	rs2279020	PMCID:PMC3125053	GABRA1	Genotype GG is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to genotype AA.	yes	= 0.031	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
982046623	CYP2C9*1	PMID:9333104	CYP2C9	CYP2C9 *1/*1 is associated with increased the maximal elimination rate (Vmax) when treated with phenytoin in Epilepsy as compared to CYP2C9 *1/*3.	yes	< 0.05	18		East Asian	Metabolism/PK	false		phenytoin
1449565567	CYP2C9*1; CYP2C9*36	PMID:27163851	CYP2C9	CYP2C9 *36 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *36 had a relative clearance of 0.1% compared to *1.	phenytoin
769249016	rs28371686	PMID:16220110	CYP2C9	Allele G is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype CC.	yes	= 0.001	109		Sub-Saharan African	Metabolism/PK,Other	false	as measured by urinary excretion of its major metabolite, S-enantiomer of 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). Statistics given for trend with various PM allele vs *1*1. [stat_test: ANOVA]	phenytoin
981859232	rs2279020	PMCID:PMC3125053	GABRA1	Allele G is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	yes	= 0.02	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
982046637	CYP2C9*1; CYP2C9*2	PMID:11668218	CYP2C9	CYP2C9 *1/*2 is associated with decreased phenytoin metabolic clearance (PMC) and phenytoin metabolic ratio (PMR) when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*1.	not stated		25		Unknown	Metabolism/PK	false		phenytoin
1449566016	HLA-B*13:01:01	PMCID:PMC5467955	HLA-B	HLA-B *13:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.88	13	40	East Asian	Toxicity	true		phenytoin
1449565504	CYP2C9*1; CYP2C9*19	PMID:27163851	CYP2C9	CYP2C9 *19 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *19 had a relative clearance of 3.4% compared to *1.	phenytoin
769250046	rs1799853	PMCID:PMC4339275	CYP2C9	Genotype TT is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to genotype CC.	not stated		14	290	European	Toxicity	false	Only one homozygote (TT = *2*2) observed amongst cases, risk not significant for heterozygotes (*1*2).	phenytoin
1449566030	HLA-B*13:25	PMCID:PMC5467955	HLA-B	HLA-B *13:25 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.25	13	40	East Asian	Toxicity	true		phenytoin
981859247	rs211037	PMCID:PMC3125053	GABRG2	Allele T is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.578	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1183701415	rs6883877	PMID:24236484	GABRA1	Genotype CT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
769250034	rs4244285	PMID:16815679	CYP2C19	Genotype AG is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype GG.	yes	< 0.001	45		Unknown	Metabolism/PK,Other	false	as measured by urinary (S)-p-HPPH and (R)-p-HPPH ratio. [stat_test: Kruskal Wallis]	phenytoin
982046630	CYP2C9*1; CYP2C9*3	PMID:11668218	CYP2C9	CYP2C9 *1/*3 is associated with decreased phenytoin metabolic clearance (PMC) and phenytoin metabolic ratio (PMR) when exposed to phenytoin in healthy individuals as compared to CYP2C9 *1/*1.	not stated		21		Unknown	Metabolism/PK	false		phenytoin
1449565513	CYP2C9*1; CYP2C9*23	PMID:27163851	CYP2C9	CYP2C9 *23 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *23 had a relative clearance of 54.8% compared to *1.	phenytoin
1183701437	rs511310	PMID:24236484		Genotype GG is not associated with decreased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype AA.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1448994156	CYP2C9*1; CYP2C9*3	PMID:14659971	CYP2C9	CYP2C9 *1/*3 is associated with increased concentrations of phenytoin in people with Epilepsy as compared to CYP2C9 *1/*1.	yes	= 0.01	28		East Asian	Metabolism/PK	false	No *3/*3 individuals were observed.	phenytoin
1449566039	HLA-B*15:01:01:01	PMCID:PMC5467955	HLA-B	HLA-B *15:01:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.15	13	40	East Asian	Toxicity	true		phenytoin
1451117900	CYP2C19*1; CYP2C19*3	PMID:31646624	CYP2C19	CYP2C19 *3 is not associated with increased risk of Exanthema when treated with phenytoin as compared to CYP2C19 *1/*1.	no	= 0.67	33	723	East Asian	Toxicity	false	CYP2C19*2 carrier status was not significantly associated with phenytoin-induced eruption in the Japanese Population.	phenytoin
1449565522	CYP2C9*1; CYP2C9*27	PMID:27163851	CYP2C9	CYP2C9 *27 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *27 had a relative clearance of 179.0% compared to *1.	phenytoin
769250028	rs1799853	PMID:16815679	CYP2C9	Genotype CT is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype CC.	yes	< 0.001	45		Unknown	Metabolism/PK	false	"as measured by urinary (S)-p-HPPH. 
[stat_test: Kruskal Wallis]. One individual genotyped to be CYP2C9*2/*3 (rs1799853T and rs1057910C) had even lower (S)-p-HPPH and (R)-p-HPPH ratio."	phenytoin
769250031	rs1057910	PMID:16815679	CYP2C9	Genotype AC is associated with decreased metabolism of phenytoin in people with Epilepsy as compared to genotype AA.	not stated		45		Unknown	Metabolism/PK,Other	false	as measured by urinary (S)-p-HPPH. [stat_test: Kruskal Wallis]. One individual genotyped to be CYP2C9*2/*3 (rs1799853T and rs1057910C) had even lower (S)-p-HPPH and (R)-p-HPPH ratio.	phenytoin
1449565531	CYP2C9*1; CYP2C9*29	PMID:27163851	CYP2C9	CYP2C9 *29 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *29 had a relative clearance of 115.7% compared to *1.	phenytoin
1184989152	CYP2C9*3	PMID:25096692	CYP2C9	CYP2C9 *3 is associated with increased risk of Maculopapular Exanthema when treated with phenytoin.	yes	= 0.011	78	130	East Asian	Toxicity	false	When comparing against both phenytoin-tolerant controls and healthy general population controls.	phenytoin
1449565989	HLA-A*11:01:01	PMCID:PMC5467955	HLA-A	HLA-A *11:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.92	13	40	East Asian	Toxicity	true		phenytoin
769248925	rs1799853	PMID:21068649	CYP2C9	Allele T is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to genotype CC.	yes	< 0.001	37		Central/South Asian	Metabolism/PK,Toxicity	false	This was further increased in undernourished individuals. Significance measured for heterozygotes of rs1799853 (*2) and rs1057910 (*3), homozygotes of either or mixed PMs.	phenytoin
1451117883	HLA-B*13:01:01	PMID:31646624	HLA-B	HLA-B *13:01:01 is not associated with increased risk of Exanthema when treated with phenytoin.	no	= 0.0074	33	721	East Asian	Toxicity	false	HLA-B*13:01 carrier status was not significantly associated with phenytoin-induced eruption in the first-stage study, but it showed association in the confirmation study.	phenytoin
1448265498	CYP2C9*3	PMID:25162219	CYP2C9	CYP2C9 *3 is associated with dose of phenytoin in children with Epilepsy.	yes	< 0.001	170		East Asian	Dosage	true	These alleles were found to influence target dose of phenytoin according to multiple regression analysis. It was also associated with a marked decrease in phenytoin metabolism. The overall model explained 74% of the variability in target dose. This study also did an analysis on the clinical usefulness of genotyping prior to phenytoin therapy.	phenytoin
1449565998	HLA-A*29:01:01:01	PMCID:PMC5467955	HLA-A	HLA-A *29:01:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
769146001	rs2032582	PMID:20417680	ABCB1	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	no		228		Central/South Asian	Efficacy	false	"This is a three allele SNP.  No association was found between any of the three alleles (C,T,A) and response to antiepileptic drugs.
Subjects on the different medications were pooled."	carbamazepine; phenobarbital; phenytoin; valproic acid
1449565484	CYP2C9*1; CYP2C9*14	PMID:27163851	CYP2C9	CYP2C9 *14 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *14 had a relative clearance of 13.3% compared to *1.	phenytoin
1183701441	rs4828696	PMID:24236484	GABRA3	Genotype TT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
769146005	rs1045642	PMID:20417680	ABCB1	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	no		282		Central/South Asian	Efficacy	false	Subjects on the different medications were pooled.	carbamazepine; phenobarbital; phenytoin; valproic acid
613978582	rs1057910	PMCID:PMC556232	CYP2C9	Allele C is associated with increased dose of phenytoin in people with Epilepsy as compared to allele A.	yes	= 0.0066	281		European	Dosage,Metabolism/PK	false		phenytoin
1183701468	rs1112122	PMID:24236484	GABRA3	Genotype GG is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.04	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1449566007	HLA-B*07:05:01	PMCID:PMC5467955	HLA-B	HLA-B *07:05:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.43	13	40	East Asian	Toxicity	true		phenytoin
1451117868	CYP2C19*1; CYP2C19*2	PMID:31646624	CYP2C19	CYP2C19 *2 is not associated with increased risk of Exanthema when treated with phenytoin as compared to CYP2C19 *1/*1.	no	= 0.22	33	723	East Asian	Toxicity	false	CYP2C19*2 carrier status was not significantly associated with phenytoin-induced eruption in the Japanese Population.	phenytoin
1449565493	CYP2C9*1; CYP2C9*16	PMID:27163851	CYP2C9	CYP2C9 *16 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *16 had a relative clearance of 14.0% compared to *1.	phenytoin
1183701464	rs10068980	PMID:24236484	GABRA1	Genotype AA is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype GG.	no	< 0.02	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
769145998	rs1128503	PMID:20417680	ABCB1	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	no		228		Central/South Asian	Efficacy	false	Subjects on the different medications were pooled.	carbamazepine; phenobarbital; phenytoin; valproic acid
613978575	rs1045642	PMCID:PMC556232	ABCB1	Allele A is not associated with increased dose of phenytoin in people with Epilepsy as compared to allele G.	no					Dosage,Metabolism/PK	false		phenytoin
1184746954	HLA-B*13:01:01	PMID:19002350	HLA-B	HLA-B *13:01:01 is associated with Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine, phenobarbital or phenytoin in people with severe cutaneous adverse reactions.	no		4	16	East Asian	Toxicity	false	The frequency of the *1301 allele (25%) was higher compared to the frequency reported for the general population (1.3%) but was not statistically significant after correction for multiple comparisons.	carbamazepine; phenobarbital; phenytoin
1450968868	HLA-B*51:01:01	PMCID:PMC6989248	HLA-B	HLA-B *51:01:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Drug Hypersensitivity, severe cutaneous adverse reactions and Epilepsy.	no		5		Unknown	Toxicity	false	"This allele was present in 3 of 5 cases alongside other HLA alleles. Case 1: HLA-A*02:01/*26:01, HLA-B*15:11/*51:01, HLA-C*03:04/*15:02; Case2: HLA-A*24:02/*26:02, HLA-B*51:01/*51:01, HLA-C*14:02/*14:02; Case 3 : HLA-A*02:01/*02:01, HLA-B*35:01/*51:01, HLA-C*03:04/*14:02. Authors state ""Korean allele frequencies of the five cases' common alleles were 9.54% for -B*51:01""."	carbamazepine; phenytoin
1451117862	CYP2C9*1; CYP2C9*27	PMID:31646624	CYP2C9	CYP2C9 *27 is not associated with increased risk of Exanthema when treated with phenytoin as compared to CYP2C9 *1/*1.	no	= 0.15	33	723	East Asian	Toxicity	false	CYP2C9*27 carrier status was not significantly associated with phenytoin-induced eruption in the Japanese Population.	phenytoin
1183701460	rs6892782	PMID:24236484	GABRA1	Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1183701456	rs1157122	PMID:24236484	GABRA1	Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.02	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1448525623	HLA-A*02:01	PMID:27888155	HLA-A	HLA-A *02:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.	yes	< 0.001	9	253	European	Toxicity	false	"The frequency of the COMBINATION of HLA-A*02:01/HLA-C*15:02 was significantly higher in cases of phenytoin-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to a group of patients tolerant to phenytoin, lamotrigine OR carbamazepine (""antiepileptic tolerant controls""). However, when the frequency was compared against patients who were phenytoin-tolerant only, a non-significant result was found. Significant results were also seen when comparing against a general population group."	phenytoin
1449565442	CYP2C9*1; CYP2C9*3	PMID:27163851	CYP2C9	CYP2C9 *3 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *3 had a relative clearance of 13.5% compared to *1.	phenytoin
1449565453	CYP2C9*1; CYP2C9*8	PMID:27163851	CYP2C9	CYP2C9 *8 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *8 had a relative clearance of 6.2% compared to *1.	phenytoin
1449565962	HLA-A*02:03:01	PMCID:PMC5467955	HLA-A	HLA-A *02:03:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.44	13	40	East Asian	Toxicity	true		phenytoin
1184989132	CYP2C9*3	PMID:25096692	CYP2C9	CYP2C9 *3 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with phenytoin.	yes	= 1.3E-11	48	412	East Asian	Toxicity	false	Several cohorts were studied. 1) In Taiwanese patients, when comparing against both phenytoin-tolerant controls and healthy general population controls. 2) In Japanese patients, when comparing against healthy general population controls. 3) In a meta-analysis of the Taiwanese, Japanese and Malaysian patients when comparing against healthy general population controls.	phenytoin
1451117840	HLA-B*15:01:01:01	PMID:31646624	HLA-B	HLA-B *15:01:01:01 is associated with increased risk of Exanthema when treated with phenytoin.	yes	= 0.0064	33	721	East Asian	Toxicity	false	HLA-B*51:01 carrier status was significantly associated with phenytoin-induced eruption in the Japanese Population.	phenytoin
769248937	rs1799853	PMID:21068649	CYP2C9	Allele T is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele C.	yes	= 0.001	33		Central/South Asian	Toxicity	false	This was further increased in undernourished individuals. Significance measured for any variant allele of rs1799853 (*2) and rs1057910 (*3).	phenytoin
1449565462	CYP2C9*1; CYP2C9*11	PMID:27163851	CYP2C9	CYP2C9 *11 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *11 had a relative clearance of 80.7% compared to *1.	phenytoin
613978601	rs3812718	PMCID:PMC556232	SCN1A	Allele T is associated with increased dose of phenytoin in people with Epilepsy as compared to allele C.	yes	= 0.014	281		European	Dosage	false		phenytoin
1448265505	CYP2C19*2; CYP2C19*3	PMID:25162219	CYP2C19	CYP2C19 *2 + *3 is associated with dose of phenytoin in children with Epilepsy.	yes	< 0.001	170		East Asian	Dosage	true	These alleles were found to influence target dose of phenytoin according to multiple regression analysis. The overall model explained 74% of the variability in target dose. This study also did an analysis on the clinical usefulness of genotyping prior to phenytoin therapy.	phenytoin
1447949113	HLA-B*15:13:01	PMID:26927288	HLA-B	HLA-B *15:13:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms, Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with phenytoin.	yes	= 5.2E-4	13	300	East Asian	Toxicity	false	The HLA-B*15:13 allele was significantly more frequent in patients with phenytoin-induced Stevens-Johnson Syndrome (SJS) or toxic epidermal necrolysis (TEN) (SJS/TEN), as well as drug reaction with eosinophilia and systemic symptoms (DRESS), as compared to phenytoin-tolerant controls. It was also significantly more frequent when compared to population controls.	phenytoin
1449565971	HLA-A*02:06:01	PMCID:PMC5467955	HLA-A	HLA-A *02:06:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
769248943	rs3812718	PMID:17001291	SCN1A	Genotypes CT + TT are associated with increased dose of phenytoin in people with Epilepsy as compared to genotype CC.	no		168		East Asian	Dosage	false	Reported as for SCN1A IVS5-91 G>A. Not significant after correction for multiple testing.	phenytoin
1184989143	CYP2C9*3	PMID:25096692	CYP2C9	CYP2C9 *3 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with phenytoin.	yes	= 7.0E-7	42	130	East Asian	Toxicity	false	Two cohorts were studies. 1) In Taiwanese patients, when comparing against both phenytoin-tolerant controls and healthy general population controls and 2) in a meta-analysis of Taiwanese and Malaysian patients, when comparing against healthy general population controls.	phenytoin
769248929	rs1057910	PMID:21068649	CYP2C9	Allele C is associated with increased plasma free phenytoin concentration when treated with phenytoin in people with Epilepsy as compared to allele A.	yes	< 0.001	37		Central/South Asian	Metabolism/PK,Toxicity	false	This was further increased in undernourished individuals. Significance measured for heterozygotes of rs1799853 (*2) and rs1057910 (*3), homozygotes of either or mixed PMs.	phenytoin
1449565471	CYP2C9*1; CYP2C9*13	PMID:27163851	CYP2C9	CYP2C9 *13 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *13 had a relative clearance of 11.7% compared to *1.	phenytoin
1449565980	HLA-A*02:07:01	PMCID:PMC5467955	HLA-A	HLA-A *02:07:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.55	13	40	East Asian	Toxicity	true		phenytoin
1451409400	CYP2C19*1; CYP2C19*2; CYP2C19*17	PMID:26122019	CYP2C19	CYP2C19 *1/*2 + *1/*17 are not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy.	no	> 0.05	64		Latino	Metabolism/PK	false	No significant difference in dose-corrected phenytoin concentrations was seen between the *1/*2 and *1/*17 genotypes (p=0.91). Univariate analysis (Table 4).	phenytoin
769248932	rs1057910	PMID:21068649	CYP2C9	Allele C is associated with increased likelihood of Drug Toxicity when treated with phenytoin in people with Epilepsy as compared to allele A.	yes	= 0.001	33		Central/South Asian	Toxicity	false	This was further increased in undernourished individuals. Significance measured for any variant allele of rs1799853 (*2) and rs1057910 (*3).	phenytoin
613978599	rs1799853	PMCID:PMC556232	CYP2C9	Allele T is not associated with increased dose of phenytoin in people with Epilepsy as compared to allele C.	no					Dosage,Metabolism/PK	false		phenytoin
1449565667	CYP2C9*1; CYP2C9*47	PMID:27163851	CYP2C9	CYP2C9 *47 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *47 had a relative clearance of 470.3% compared to *1.	phenytoin
981954817	rs2032582	PMID:18812236	ABCB1	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
981859074	HLA-B*13:01:01	PMID:20235791	HLA-B	HLA-B *13:01:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	yes	= 0.0154	26	113	East Asian	Toxicity	false		phenytoin
1449566177	HLA-C*03:03:01	PMCID:PMC5467955	HLA-C	HLA-C *03:03:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.15	13	40	East Asian	Toxicity	true		phenytoin
769259088	rs1057910	PMID:21537551	CYP2C9	Allele C is not associated with likelihood of adverse reaction when treated with phenytoin in people with Epilepsy as compared to allele A.	no					Toxicity	false		phenytoin
981954829	rs1045642	PMID:18812236	ABCB1	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1449565676	CYP2C9*1; CYP2C9*48	PMID:27163851	CYP2C9	CYP2C9 *48 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *48 had a relative clearance of 108.0% compared to *1.	phenytoin
981859086	HLA-DRB1*16:02:01	PMID:20235791	HLA-DRB1	HLA-DRB1 *16:02:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	yes	= 0.0128	26	113	East Asian	Toxicity	false		phenytoin
1449566186	HLA-C*03:04:01:01	PMCID:PMC5467955	HLA-C	HLA-C *03:04:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.69	13	40	East Asian	Toxicity	true		phenytoin
981954839	rs2032582	PMID:18812236	ABCB1	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1448614858	HLA-B*07:02:01; HLA-B*15:02:01	PMID:28391407	HLA-B	HLA-B *15:02:01 is not associated with likelihood of drug reaction with eosinophilia and systemic symptoms or Stevens-Johnson Syndrome when exposed to phenytoin as compared to HLA-B *07:02:01.	no	= 0.0402	36	100	East Asian	Toxicity	false	Note: the authors specify that HLA-B*15:02 was genotyped, not HLA-B*15:02:01.	phenytoin
1449565685	CYP2C9*1; CYP2C9*49	PMID:27163851	CYP2C9	CYP2C9 *49 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *49 had a relative clearance of 249.8% compared to *1.	phenytoin
1449566195	HLA-C*04:01:01:01	PMCID:PMC5467955	HLA-C	HLA-C *04:01:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.43	13	40	East Asian	Toxicity	true		phenytoin
769259087	rs1799853	PMID:21537551	CYP2C9	Allele T is not associated with likelihood of adverse reaction when treated with phenytoin in people with Epilepsy as compared to allele C.	no					Toxicity	false		phenytoin
981859091	HLA-C*08:01:01	PMID:20235791	HLA-C	HLA-C *08:01:01 is associated with increased risk of Toxic Epidermal Necrolysis or Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	yes	= 0.0281	26	113	East Asian	Toxicity	false		phenytoin
1449565695	CYP2C9*1; CYP2C9*50	PMID:27163851	CYP2C9	CYP2C9 *50 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *50 had a relative clearance of 39.8% compared to *1.	phenytoin
1449566204	HLA-C*07:02:01:01	PMCID:PMC5467955	HLA-C	HLA-C *07:02:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
1449566150	HLA-B*55:02:01	PMCID:PMC5467955	HLA-B	HLA-B *55:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
981859108	HLA-B*15:02:01; HLA-B*46:01:01	PMID:21216202	HLA-B	HLA-B *15:02:01 + *46:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	no					Toxicity	false	IMPORTANT NOTE: This is a case report. There are 2 cases in this paper, this is the second case who has HLA-B*1502/B*4601 genotype.	phenytoin
1449565639	CYP2C9*1; CYP2C9*44	PMID:27163851	CYP2C9	CYP2C9 *44 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *44 had a relative clearance of 58.9% compared to *1.	phenytoin
981859111	HLA-B*46:01:01; HLA-B*51:02:01	PMID:21334226	HLA-B	HLA-B *46:01:01 + *51:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	no					Toxicity	false	IMPORTANT NOTE: This study have two cases only. Both cases do not have HLA-B*15:02 allele. This is the first case, who has HLA-B*4601/B*5102	phenytoin
981859105	HLA-B*15:01:01:01; HLA-B*15:02:01; HLA-B*54:01:01	PMID:21216202	HLA-B	HLA-B *15:01:01:01 + *54:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	no					Toxicity	false	IMPORTANT NOTE: This is a case report. There are 2 cases in this paper, this is the first case who has HLA-B*1501/B*5401 genotype.	phenytoin
1450377173	rs1801280	PMCID:PMC4989831	NAT2	Allele C is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele T.	yes	< 0.05	60		Unknown	Toxicity	false	The C allele was associated with an increased risk of experiencing phenytoin toxicity in patients taking both phenytoin and isoniazid. It is hypothesized that decreased isoniazid metabolism by NAT2 enzymes carrying this variant increases the isoniazid-induced inhibition of phenytoin metabolism.	isoniazid; phenytoin
981859117	HLA-B*15:02:01	PMID:22500513	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Epilepsy.	not stated		14	16	East Asian	Toxicity	false		carbamazepine; phenytoin
1449566159	HLA-B*56:01:01	PMCID:PMC5467955	HLA-B	HLA-B *56:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.25	13	40	East Asian	Toxicity	true		phenytoin
1451271980	HLA-B*15:02:01	PMCID:PMC5467955	HLA-B	HLA-B *15:02:01 is associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.	yes	= 5.63e-15	56	179	East Asian	Toxicity	true	in pooled analysis (all 3 drugs) this was a clear association. Authors suggest this is driven by carbamazepine.	carbamazepine; lamotrigine; phenytoin
1451148752	rs780801862	PMID:32423989	CYP2C9	Allele T is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele A.	not stated					Metabolism/PK	false	Variant referred to in the paper as N218I.	flurbiprofen; naproxen; phenytoin; warfarin
981859114	HLA-B*37:01:01; HLA-B*46:01:01	PMID:21334226	HLA-B	HLA-B *46:01:01 + *37:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in Epilepsy.	no					Toxicity	false	IMPORTANT NOTE: This study have two cases only. Both cases do not have HLA-B*15:02 allele. This is the second case, who has HLA-B*3701/B*4601 allele	phenytoin
1451148748	rs182132442	PMID:32423989	CYP2C9	Allele A is associated with decreased catalytic activity of CYP2C9 when assayed with flurbiprofen, naproxen, phenytoin or warfarin as compared to allele C.	not stated					Metabolism/PK	false	Variant referred to in the paper as P279T, which is also the CYP2C9*29 allele.	flurbiprofen; naproxen; phenytoin; warfarin
1184746798	rs3130501	PMCID:PMC3173287	POU5F1	Allele G is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele A.	yes	= 1.73E-8	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
1444935593	HLA-C*08:01	PMID:25495410	HLA-C	HLA-C *08:01 is associated with increased risk of Maculopapular Exanthema when treated with phenytoin.	yes	< 0.0001	2	225	Latino	Toxicity	false	The frequency of the HLA-C*08:01 allele in the phenytoin-induced maculopapular exanthema group was higher than that in the phenytoin tolerant group and in the general Mexican Mestizo population. Corrected p-values.	phenytoin
1449565648	CYP2C9*1; CYP2C9*45	PMID:27163851	CYP2C9	CYP2C9 *45 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *45 had a relative clearance of 2.0% compared to *1.	phenytoin
1445379985	rs1934969	PMID:26122019	CYP2C9	Genotypes AT + TT is associated with increased dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA.	yes	= 0.03	64		Latino	Metabolism/PK	false	Patients with the AT and TT genotypes had, on average, a 1.7X higher dose-corrected phenytoin concentration as compared to patients with the AA genotype. Multivariate analysis, adjusted for sex and age. The frequency of the T allele was also higher in the supratherapeutic group (phenytoin plasma concentrations <20 ug/ml) as compared to the subtherapeutic group (<10 ug/ml; p=0.05).	phenytoin
1450377157	rs1208	PMCID:PMC4989831	NAT2	Allele G is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele A.	yes	< 0.05	60		Unknown	Toxicity	false	The G allele was associated with an increased risk of experiencing phenytoin toxicity in patients taking both phenytoin and isoniazid. It is hypothesized that decreased isoniazid metabolism by NAT2 enzymes carrying this variant increases the isoniazid-induced inhibition of phenytoin metabolism.	isoniazid; phenytoin
769171557	rs2304016	PMID:18784617	SCN2A	Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.	yes	= 0.02	177	200	East Asian	Efficacy	false		carbamazepine; lamotrigine; oxcarbazepine; phenytoin; topiramate
1449566168	HLA-C*01:02:01	PMCID:PMC5467955	HLA-C	HLA-C *01:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.92	13	40	East Asian	Toxicity	true		phenytoin
1449565657	CYP2C9*1; CYP2C9*46	PMID:27163851	CYP2C9	CYP2C9 *46 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *46 had a relative clearance of 56.9% compared to *1.	phenytoin
1450377165	rs1799931	PMCID:PMC4989831	NAT2	Allele A is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele G.	yes	< 0.05	60		Unknown	Toxicity	false	The A allele was associated with an increased risk of experiencing phenytoin toxicity in patients taking both phenytoin and isoniazid. It is hypothesized that decreased isoniazid metabolism by NAT2 enzymes carrying this variant increases the isoniazid-induced inhibition of phenytoin metabolism.	isoniazid; phenytoin
1449566114	HLA-B*40:02:01	PMCID:PMC5467955	HLA-B	HLA-B *40:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.43	13	40	East Asian	Toxicity	true		phenytoin
1449565603	CYP2C9*1; CYP2C9*40	PMID:27163851	CYP2C9	CYP2C9 *40 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	no	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *40 had a relative clearance of 247.2% compared to *1.	phenytoin
981859149	rs1045642	PMCID:PMC3125053	ABCB1	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.39	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1450377146	rs1799930	PMCID:PMC4989831	NAT2	Allele A is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele G.	yes	< 0.05	60		Unknown	Toxicity	false	The A allele was associated with an increased risk of experiencing phenytoin toxicity in patients taking both phenytoin and isoniazid. It is hypothesized that decreased isoniazid metabolism by NAT2 enzymes carrying this variant increases the isoniazid-induced inhibition of phenytoin metabolism.	isoniazid; phenytoin
1449565612	CYP2C9*1; CYP2C9*41	PMID:27163851	CYP2C9	CYP2C9 *41 is associated with increased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *41 had a relative clearance of 365.6% compared to *1.	phenytoin
1184989037	CYP2C9*3	PMID:25096692	CYP2C9	CYP2C9 *3 is associated with increased risk of severe cutaneous adverse reactions when treated with phenytoin.	yes	= 1.1E-17	90	542	East Asian	Toxicity	false	Multiple cohorts were studied. 1) A GWAS discovery cohort of Taiwanese patients with healthy general population controls, 2) a replication cohort of Taiwanese patients with phenytoin-tolerant controls, 3) a combination of the discovery and replication cohorts of Taiwanese patients (population and tolerant controls combined), 4) in Malaysian patients with healthy general population controls and 5) in a meta-analysis of Taiwanese, Japanese and Malaysian patients with healthy general population controls. Severe cutaneous adverse reactions (SCARs) include Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reactions with eosinophilia and systemic symptoms (DRESS).	phenytoin
1449566123	HLA-B*46:01:01	PMCID:PMC5467955	HLA-B	HLA-B *46:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
1448614807	rs1799853	PMID:28391407	CYP2C9	Allele T is not associated with drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to allele C.	no	= 0.6264	36	100	East Asian	Toxicity	false		phenytoin
1183680863	HLA-B*15:02:01	PMID:23692434	HLA-B	HLA-B *15:02:01 is not associated with risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	no	= 0.045	15	75	East Asian	Toxicity	false	Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele did NOT have a significantly greater risk of developing SJS/TEN, compared to those without the allele, after p-value adjustment for multiple comparisons using Bonferroni's correction (p < 0.01 was considered significant). This study was done in a case-control format, where 15 cases were compared against 75 controls; cases developed SJS/TEN on phenytoin, controls did not. However, please note that this paper also conducted a meta-analysis which included this study plus another study, and found significant results for phenytoin-induced SJS/TEN in HLA-B *15:02 carriers.	phenytoin
1449566132	HLA-B*51:02:01	PMCID:PMC5467955	HLA-B	HLA-B *51:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.25	13	40	East Asian	Toxicity	true		phenytoin
1449565621	CYP2C9*1; CYP2C9*42	PMID:27163851	CYP2C9	CYP2C9 *42 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *42 had a relative clearance of 0.1% compared to *1.	phenytoin
981751120	rs17183814	PMCID:PMC2767285	SCN2A	Allele A is associated with resistance to carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	yes	= 0.06	336	160	Central/South Asian	Efficacy	false	p value was above significance level after correction for multiple testing.  Authors note that association was found at the allele level but not at the genotype level, and that this may be due to a low number of AA individuals.	carbamazepine; phenobarbital; phenytoin; valproic acid
1448614798	rs1799853	PMID:28391407	CYP2C9	Allele T is associated with increased likelihood of Stevens-Johnson Syndrome when exposed to phenytoin as compared to allele C.	yes	= 0.0042	136		East Asian	Toxicity	false	The frequency of the T allele was higher in patients with drug reaction with Stevens-Johnson Syndrome (SJS), as compared to phenytoin-tolerant controls and remained significant in multiple logistic regression. Combining HLA-B*15:02 allele with the T allele and Chinese ancestry improved the specificity of testing to 96%.	phenytoin
1184469326	CYP2D6*1; CYP2D6*41	PMID:24915025	CYP2D6	CYP2D6 *1/*41 is associated with decreased plasma endoxifen level when treated with phenytoin and tamoxifen in people with Epilepsy.	no		1		Unknown	Metabolism/PK	false	Case study. Patient has Breast Neoplasms and is treated tamoxifen. Additional to tamoxifen medications are trastuzumab, phenytoin, valproic acid, clobazam, diltiazem, and hydrochlorothiazide.	phenytoin; tamoxifen
1449565630	CYP2C9*1; CYP2C9*43	PMID:27163851	CYP2C9	CYP2C9 *43 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *43 had a relative clearance of 2.7% compared to *1.	phenytoin
1449566141	HLA-B*54:01:01	PMCID:PMC5467955	HLA-B	HLA-B *54:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 1.00	13	40	East Asian	Toxicity	true		phenytoin
1450377135	rs1799929	PMCID:PMC4989831	NAT2	Allele T is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain and Tuberculous meningitis NOS as compared to allele C.	yes	< 0.05	60		Unknown	Toxicity	false	The T allele was associated with an increased risk of experiencing phenytoin toxicity in patients taking both phenytoin and isoniazid. It is hypothesized that decreased isoniazid metabolism by NAT2 enzymes carrying this variant increases the isoniazid-induced inhibition of phenytoin metabolism.	isoniazid; phenytoin
1184987970	HLA-B*15:02:01	PMID:23551241	HLA-B	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with phenytoin in children.	no	= 0.35	17	17	East Asian	Toxicity	true	Children who carried the *15:02 allele did not have an increased risk of developing phenytoin-induced severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).	phenytoin
1445391811	rs1045642	PMID:26122019	ABCB1	Genotype AG is not associated with dose-adjusted trough concentrations of phenytoin in people with Epilepsy as compared to genotype AA.	no	= 0.18	64		Latino	Metabolism/PK	false	No significant difference in dose-corrected phenytoin concentrations was seen between the AA and AG genotypes. Univariate analysis. Please note that alleles have been complemented to the plus chromosomal strand.	phenytoin
981859171	rs1128503	PMCID:PMC3125053	ABCB1	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.71	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1448614847	HLA-B*07:02:01; HLA-B*13:01:01	PMID:28391407	HLA-B	HLA-B *13:01:01 is not associated with likelihood of Stevens-Johnson Syndrome when exposed to phenytoin as compared to HLA-B *07:02:01.	no	= 0.4637	36	100	East Asian	Toxicity	false		phenytoin
1448614832	HLA-B*07:02:01; HLA-B*13:01:01	PMID:28391407	HLA-B	HLA-B *13:01:01 is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to HLA-B *07:02:01.	yes	= 0.0001	136		East Asian	Toxicity	false	The frequency of the *13:01 allele was higher in patients with drug reaction with eosinophilia and systemic symptoms (DRESS), as compared to phenytoin-tolerant controls and remained significant in multiple logistic regression. Combined analysis with HLA- B*13:01/HLA-B*56:02/04 and CYP2C19*3 and omeprazole co-medication showed the highest accuracy in predicting DRESS/DHS (86.0%)	phenytoin
981859179	rs2032582	PMCID:PMC3125053	ABCB1	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.	yes	= 0.03	402		Central/South Asian	Efficacy	false	"However, The study reports that the genotype frequencies of 2677G>T ABCB1 polymorphism did not differ significantly in the drug-resistant versus the
drug-responsive epilepsy patients for GT genotype (P =0.71, OR = 1.14, 95% CI = 0.55 - 2.36), for TT genotype (P = 0.87, OR = 1.06, 95% CI = 0.49 - 2.26) and for AT genotype (P = 0.39, OR = 0.53, 95% CI = 0.13 - 2.24). (The alleles are given on the negative strand in the article.)"	carbamazepine; phenytoin; valproic acid
1449565576	CYP2C9*1; CYP2C9*37	PMID:27163851	CYP2C9	CYP2C9 *37 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *37 had a relative clearance of 37.7% compared to *1.	phenytoin
1448614825	rs4986893	PMID:28391407	CYP2C19	Allele G is not associated with likelihood of Stevens-Johnson Syndrome when exposed to phenytoin as compared to allele A.	no	= 0.5763	36	100	East Asian	Toxicity	false		phenytoin
1183680889	HLA-B*15:02:01	PMID:23692434	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with phenytoin in people with Epilepsy.	yes	= 3E-4	41	188	East Asian	Toxicity	false	Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele have a significantly greater risk of developing SJS/TEN, compared to those without the allele. This was a meta-analysis, which included two case-control studies, where 41 cases were compared against 188 controls; cases developed SJS/TEN on phenytoin, controls did not.	phenytoin
1449566096	HLA-B*38:02:01	PMCID:PMC5467955	HLA-B	HLA-B *38:02:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.17	13	40	East Asian	Toxicity	true		phenytoin
1450377092	rs1041983	PMCID:PMC4989831	NAT2	Allele T is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain or Tuberculous meningitis NOS as compared to allele C.	yes	< 0.05	60		Unknown	Toxicity	false	The T allele was associated with an increased risk of experiencing phenytoin toxicity in patients taking both phenytoin and isoniazid. It is hypothesized that decreased isoniazid metabolism by NAT2 enzymes carrying this variant increases the isoniazid-induced inhibition of phenytoin metabolism.	isoniazid; phenytoin
1449565585	CYP2C9*1; CYP2C9*38	PMID:27163851	CYP2C9	CYP2C9 *38 is not associated with clearance of phenytoin as compared to CYP2C9 *1.	no	> 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *38 had a relative clearance of 75.6% compared to *1.	phenytoin
1448614816	rs4986893	PMID:28391407	CYP2C19	Allele A is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when exposed to phenytoin as compared to allele G.	yes	= 0.0414	136		East Asian	Toxicity	false	The frequency of the A allele was higher in patients with drug reaction with eosinophilia and systemic symptoms (DRESS), as compared to phenytoin-tolerant controls and remained significant in multiple logistic regression. Combined analysis with HLA- B*13:01/HLA-B*56:02/04 and CYP2C19*3 and omeprazole co-medication showed the highest accuracy in predicting DRESS/DHS (86.0%)	phenytoin
1184987994	HLA-B*15:02:01	PMID:23551241	HLA-B	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine, phenobarbital or phenytoin in children.	no	= 0.53	40	40	East Asian	Toxicity	true	Carbamazepine n=3, phenobarbital n=20, phenytoin n=17. Children who carried the *15:02 allele did not have an increased risk of developing antiepileptic-induced severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Negative results were also seen when considering phenobarbital and phenytoin subgroups.	carbamazepine; phenobarbital; phenytoin
1451151749	rs1799853	PMCID:PMC7221122	CYP2C9	Allele T is associated with increased risk of Ataxia, Diplopia, Dizziness or Dysarthria due to phenytoin in people with Epilepsy as compared to allele C.	yes	= 0.001	67		Unknown	Efficacy	false	The T allele is also referred to in the paper as the CYP2C9*2 allele. Patients carrying the CYP2C9*2 or *3 alleles were significantly more likely to experience vestibular-cerebellar adverse drug reactions.	phenytoin
1449565594	CYP2C9*1; CYP2C9*39	PMID:27163851	CYP2C9	CYP2C9 *39 is associated with decreased clearance of phenytoin as compared to CYP2C9 *1.	yes	< 0.05			Unknown	Metabolism/PK	false	In vitro assay of relative activity of CYP2C9 alleles in phenytoin clearance in insect microsomes. *39 had a relative clearance of 1.1% compared to *1.	phenytoin
981859192	rs17183814	PMCID:PMC3125053	SCN2A	Allele A is associated with non-response when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	yes	= 0.03	402		Central/South Asian	Efficacy	false	Authors note that association was found at the allele level but not at the genotype level, and that this may be due to a low number of AA individuals.	carbamazepine; phenytoin; valproic acid
1184746848	rs3094188	PMCID:PMC3173287	PSORS1C3	Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele C.	yes	= 2.93E-8	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
1449566105	HLA-B*40:01:01	PMCID:PMC5467955	HLA-B	HLA-B *40:01:01 is not associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome due to phenytoin.	no	= 0.74	13	40	East Asian	Toxicity	true		phenytoin